Modality
Vaccine
MOA
KIF18Ai
Target
BTK
Pathway
Autophagy
MDDHuntington's
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
~Apr 2018
→ ~Jul 2019
Phase 3
Oct 2019
Phase 3Current
NCT06224700
2,229 pts·Huntington's
2019-10→TBD·Not yet recruiting
NCT08946581
2,834 pts·MDD
2021-03→TBD·Recruiting
5,063 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q42020Q2Q3Q42021
P3
Not yet…
P3
Recruit…
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06224700 | Phase 3 | Huntington's | Not yet recr... | 2229 | CR |
| NCT08946581 | Phase 3 | MDD | Recruiting | 2834 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| 369-8021 | Hansoh Pharma | Approved | BTK |